Home » EU Buys $74 Million Worth of Remdesivir
EU Buys $74 Million Worth of Remdesivir
The European Commission signed a $74 million contract with Gilead Sciences for a supply of remdesivir for treatment for 30,000 patients with severe COVID-19 over the next few months.
The European Medicines Agency approved remdesivir this month, marketed as Veklury, for treatment of COVID-19 patients with pneumonia requiring supplemental oxygen.
The commission said it plans to procure a further supply of the antiviral to cover additional needs in the future.
Upcoming Events
-
07May
-
14May
-
30May